Clinical Trials Logo

Complement 3 Glomerulopathy clinical trials

View clinical trials related to Complement 3 Glomerulopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05809531 Active, not recruiting - C3 Glomerulopathy Clinical Trials

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

VALE
Start date: May 29, 2023
Phase: Phase 3
Study type: Interventional

This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

NCT ID: NCT05162066 Terminated - Clinical trials for Membranous Nephropathy

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

RENEW
Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

NCT ID: NCT05067127 Active, not recruiting - C3 Glomerulopathy Clinical Trials

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

VALIANT
Start date: November 12, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

NCT ID: NCT04729062 Available - C3 Glomerulopathy Clinical Trials

C3G/Primary IC-MPGN EAP

Start date: n/a
Phase:
Study type: Expanded Access

This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.

NCT ID: NCT04572854 Active, not recruiting - Renal Transplant Clinical Trials

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NOBLE
Start date: February 23, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.